Table 1 Characteristics of the included studies
ID | Author | Year | Country | Sample size | Sampling | Age(years) | Treatments (Recurrence) | Follow_up | Type | Risk of bias | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Akbulut S | 2011 | Turkey | 4 | Non-Randomized | 30–42 | Oral steroid + MTX (0/4) | 2–9 months | IGM | 8 | [21] |
2 | Akcan A | 2014 | Turkey | 74 | Non-Randomized | 36.6 | Excision (4/51), Steroid + surgery (0/21) | 3–170 months | IGM | 3 | [22] |
3 | Al-Jarrah A | 2013 | Oman | 20 | Non-Randomized | 37.5 | Antibiotic (0/19), Excision (0/1) | 11–33 months | IGM | 5 | [23] |
4 | Alrayes A | 2019 | Bahrain | 18 | Non-Randomized | 39 | Excision (0/18) | 12‐24 months | IGM | 6 | [1] |
5 | Altintoprak F | 2015 | Turkey | 28 | Non-Randomized | 35.7 | Topical steroid (3/28) | 12–72 months | IGM | 5 | [24] |
6 | Aslan H | 2018 | Turkey | 39 | Non-Randomized | Conservative:38.44 ± 9.6 surgery:36.05 ± 7.44 | Antibiotic (4/18), Mastectomy (1/21) | conservative: 9.05 ± 14.5 months surgery:10.28 ± 10.08 months | IGM | 3 | [3] |
7 | Asoglu O | 2005 | Turkey | 18 | Non-Randomized | 41.5 (16–80) | Antibiotic + surgery (1/18) | 36 (6–60 months) | IGM | 6 | [25] |
8 | Atalay C | 2011 | Turkey | 51 | Non-Randomized | 33 (22–57) | Excision (3/50), Mastectomy (0/1) | 38 (12–58 months) | IGM | 3 | [26] |
9 | Azlina, A. F | 2003 | Malaysia | 12 | Non-Randomized | 36.5 | Oral steroid (6/12) | 2–6 months | CGM | 8 | [27] |
10 | Baslaim M. M | 2007 | Saudi Arabia | 17 | Non-Randomized | 34 (21–45 years) | Antibiotic + surgery (0/17) | 24 (15–42 months) | IGM | 6 | [28] |
11 | Bouton M. E | 2015 | USA | 27 | Non-Randomized | 33 | Observation (3/27), Excision (1/9) | 7.4 (6–24 months) | IGM | 6 | [29] |
12 | Calis H | 2014 | Turkey | 13 | Non-Randomized | 44 (25–77) | Oral steroid (2/12), Mastectomy (0/1) | 24 months | IGM | 6 | [17] |
13 | Cetinkaya G | 2021 | Turkey | 118 | Non-Randomized | 35 (21–65) | Oral steroid (8/36), Antibiotic (4/21), Observation (1/50), Imuran (0/2) | 70 (16–124 months) | IGM | 4 | [30] |
14 | Chirappapha P | 2018 | Thailand | 36 | Non-Randomized | 38 (21–81) | Oral steroid (1/6), Drainag (3/7), Excision (8/23) | 20.73 (1.26–118.8 months) | IGM | 3 | [31] |
15 | Co M | 2018 | China | 88 | Non-Randomized | 33 (20–54) | Oral steroid (9/62), Antibiotic (4/22), Excision (1/4) | 14 (4–51 months) | IGM | 6 | [32] |
16 | Cornejo-Juarez, P | 2014 | Mexico | 58 | Non-Randomized | 38 ± 12 | Oral steroid (2/8), Antibiotic (6/20), Antibiotic + steroid (3/20), Observation (3/7), Excision (1/3) | 16.7 ± 13.8 months | IGM | 3 | [33] |
17 | Dag A | 2021 | Turkey | 18 | Non-Randomized | 34.2(25–42) | Excision + oncoplastic breast surgery (2/18) | 20 (6–44 months) | IGM | 6 | [34] |
18 | Elzahaby I. A | 2016 | Egypt | 30 | Non-Randomized | 33(23–43) | Excision (0/30) | 19 (8–44 months) | IGM | 7 | [35] |
19 | Erozgen F | 2010 | Turkey | 27 | Non-Randomized | 35.3 (22–52) | Oral steroid (0/4), Drainage + steroid (1/14), Excision + steroid (0/9) | 7 (1–48 months) | IGM | 6 | [36] |
20 | Erturk T. F | 2021 | Turkey | 86 | Non-Randomized | Conservative:37.2 (23–63) surgery:36.8 (24–65) | Intralesional injection of steroid + topical steroid (0/38), Excision (15/48) | 12-month | IGM | 4 | [37] |
21 | Gopalakrishnan Nair C | 2014 | India | 22 | Randomized | 32.85 | Oral steroid (1/22) | 24 months | IGM | 5 | [38] |
22 | Govindasamy A | 2016 | India | 26 | Non-Randomized | 20–53 | Excision (0/26) | 12–84 months | GM | 6 | [39] |
23 | Hur S. M | 2013 | Korea | 50 | Non-Randomized | 37.1 ± 7.9 | Oral steroid (9/13), Antibiotic (2/3), Observation (1/8), Drainage (10/14), Excision (1/12) | 32.0 ± 18.1 months | GLM | 4 | [40] |
24 | Kafadar M. T | 2021 | Turkey | 17 | Non-Randomized | 40.4 ± 5.3 | Oral steroid + MTX (4/17) | 2–3 months of treatment | IGM | 8 | [41] |
25 | Karanlik H | 2014 | Turkey | 60 | Randomized | 35 (18–58) | Oral steroid (7/23), Steroid + surgical (0/37) | conservative:12 (2–18) months surgery + conservative:38 (22–78 months) | IGM | 2 | [42] |
26 | Kaviani A | 2018 | Iran | 374 | Non-Randomized | 34.06 ± 6.7 | Oral steroid (39/142), antibiotic (22/154), MTX (1/13), NSAID (26/140), Observation (10/66), Surgical procedures (89/158) | – | IGM | 6 | [43] |
27 | Kayahan M | 2012 | Turkey | 31 | Non-Randomized | 35 (27–62) | Oral steroid (1/12), Antituberculosis (0/1), Drainage (3/6), Excision (1/12) | 27.8 (9–124 months) | GM | 5 | [44] |
28 | Kehribar D. Y | 2020 | Turkey | 33 | Non-Randomized | 38.64 ± 6.9 | Oral steroid + MTX (0/33) | 24 months | IGM | 6 | [45] |
29 | Koksal H | 2021 | Turkey | 108 | Non-Randomized | 35.5 (21–68) | Oral steroid (2/18), Wait-and-watch or only antibiotic (3/42), Surgical procedures (5/48) | Up to 20 months | IGM | 4 | [46] |
30 | Liao H | 2020 | China | 28 | Non-Randomized | 32 (26–43) | Surgical procedures (1/24) | 20 (11–40 months) | GLM | 6 | [47] |
31 | Mizrakli T | 2014 | Turkey | 49 | Non-Randomized | 34.3 ± 4.37 | Antibiotic (0/1), Oral steroid + MTX (0/40), Antituberculosis (0/5), NSAID (0/2), Excision (0/1) | At least 6 months | GM | 6 | [48] |
32 | Nair C. G | 2015 | India | 23 | Non-Randomized | 33.42 | Antibiotic + steroid (1/23) | 24 months | IGM | 5 | [49] |
33 | Ocal K | 2010 | Turkey | 16 | Non-Randomized | 34 (24–51) | Excision (3/16) | 24 (6–36 months) | GM | 5 | [50] |
34 | Ozel L | 2012 | Turkey | 8 | Non-Randomized | 37( 27–48) | Antibiotic + surgery (2/8) | 12 months | GM | 8 | [51] |
35 | Papila Kundaktepe B | 2021 | Turkey | 60 | Non-Randomized | 32.77 ± 6.03 (23–49) | MTX (8/60) | 831 ± 547 days | IGM | 5 | [51] |
36 | Ringsted S | 2021 | Oregon | 20 | Non-Randomized | 32(16–42) | Oral steroid (5/12), MTX (0/5), Steroid + surgery (0/3) | 27 (5–63 months) | IGM | 6 | [52] |
37 | Salehi M | 2014 | Iran | 59 | Non-Randomized | conservative:30.3 ± 6.38 surgery:36.74 ± 13.51 | Antibiotic + steroid (1/20), Partial mastectomy (32/39) | 12 months | IGM | 6 | [53] |
38 | Sen Oran E | 2013 | Turkey | 46 | Non-Randomized | 33 (28–55) | Oral steroid (5/25), Excision (3/18), Steroid + surgery (0/3) | 35.4 (3–135 months) | IGM | 3 | [54] |
39 | Shin Y. D | 2017 | South Korea | 34 | Non-Randomized | 37(24—57) | Excision (5/20), steroid + drainage (1/14) | 45.5 (22–98 months) | GLM | 4 | [55] |
40 | Shojaee L | 2021 | Iran | 87 | Non-Randomized | 34 | Oral steroid (9/23), Excision (7/17), steroid + drainage (9/47) | 26 (8–48 months) | IGM | 3 | [56] |
41 | Skandarajah, A | 2015 | Australia | 11 | Non-Randomized | 40 | Oral steroid (1/3), Antibiotic + surgery (3/5) | 6 (3 months–15 years) | IGM | 8 | [57] |
42 | Tan Q. T | 2019 | Singapore | 113 | Non-Randomized | 36.2(25–63) | Oral steroid (16/73), Antibiotic (19/79), MTX (1/1), Observation (0/5), Surgical procedures (6/24) | 252 days | GM | 5 | [4] |
43 | Tekgoz E | 2020 | Turkey | 53 | Non-Randomized | 37.2 ± 6.6 | Oral steroid (0/3), Oral steroid + MTX (1/41), Azathioprine + steroid (0/3), Observation (0/1), Excision (3/3), MTX + surgery (0/2) | 13.83 (1.61–100.83 months) | IGM | 6 | [2] |
44 | Toktas O | 2021 | Turkey | 78 | Non-Randomized | 36.7 ± 1.4 | Oral steroid (15/32), Intralesional injection of steroid + topical steroid (4/46) | 23.2 ± 9.1 | IGM | 4 | [6] |
45 | Velidedeoglu M | 2016 | Turkey | 10 | Non-Randomized | 38.4 ± 8.3(29–52) | Antibiotic (0/1), Drainage + antibiotic (1/5), Drainage + antibiotic + steroid (0/4) | 21 (11–26 months) | IGM | 8 | [58] |
46 | Wang J | 2021 | China | 200 | Non-Randomized | 38 | Oral steroid (24/104), Surgical procedures (8/156) | 15.64 (12–36months) | IGM | 3 | [59] |
47 | Yabanoglu H | 2015 | Turkey | 77 | Non-Randomized | Surgery:36 (28–68) Conservative:37 (28–59) | Oral steroid (9/44), Excision (0/31), Mastectomy (0/2) | 16.57 ± 18.57 | IGM | 4 | [60] |
48 | Yau F. M | 2010 | Canada | 11 | Non-Randomized | 37.4 (23–49) | Antibiotic + surgery (8/11) | 18.6 months | GM | 6 | [61] |
49 | Zhang X | 2020 | China | 53 | Non-Randomized | 34.6 ± 5.9 | Excision (4/25), Surgery + traditional chinese medicine (Yanghe decoction) (0/28) | 13.2 ± 10.0 months | IGM | 5 | [14] |
50 | Zhang X | 2020 | China | 68 | Non-Randomized | 35 (22–55) | Excision (3/68) | 24 months | IGM | 6 | [62] |
51 | Ahmed, Y. S | 2016 | Egypt | 13 | Non-Randomized | 35.53 ± 7.25 (27–51) | Excision (2/13) | – | IGM | 7 | [63] |
52 | Akin M | 2017 | Turkey | 11 | Non-Randomized | 35.5 (29–45) | Antibiotic + steroid (0/11) | 60 (16–110 months) | IGM | 7 | [64] |
53 | Atak T | 2015 | Turkey | 50 | Non-Randomized | 39.07 ± 11.5 | Oral steroid (1/6), Antibiotic + anti inflammatory agent (1/11), Drainage (12/16), Excision (1/7) | 24.85 ± 19.7 months | IGM | 5 | [65] |
54 | Basim P | 2021 | Turkey | 122 | Non-Randomized | 34.1 (29–47) | Oral steroid (8/28), Excision (6/19), Steroid + surgery (5/75) | 32.5 (19–67 months) | IGM | 3 | [16] |
55 | Cetin K | 2019 | Turkey | 124 | Randomized | 33.9 ± 6.8 (20–58) | Oral steroid (6/42), Topical steroid (5/42), Topical + oral steroid (6/40) | 94 ± 28 (55–191 weeks) | GM | 3 | [66] |
56 | Emre A | 2018 | Turkey | 32 | Non-Randomized | 40.3 ± 10.7(26–70) | Oral steroid (1/3), Antibiotic (2/10), Antibiotic + steroid (1/9), Anti TB + antibiotic (0/2), Anti TB (0/1), Antibiotic + chemotherapy (0/1), Observation (1/6) | 687 ± 618 (5–1800 days) | IGM | 7 | [67] |
57 | Galea M. H | 1989 | England | 6 | Non-Randomized | 34 | Excision (2/6) | – | GLM | 8 | [68] |
58 | McLean, N. R | 2019 | United Kingdom | 4 | Non-Randomized | 47.5 (26–62) | Antibiotic + surgery (0/1), Steroid + antibiotic + mastectomy (0/3) | 30 months | IGM | 8 | [69] |
59 | Oak J | 2021 | India | 40 | Non-Randomized | 33 | Oral steroid + MTX (2/40) | 12 months | IGM | 5 | [70] |
60 | Oran E. S | 2013 | Turkey | 46 | Non-Randomized | 33 (28–55) | Oral steroid (5/25), Excision (3/18), Steroid + surgery (0/3) | 35.4 (3–135 months) | IGM | 4 | [71] |
61 | Pandey T. S | 2021 | USA | 49 | Non-Randomized | 35 (24–67) | Oral steroid (10/44), Observation (0/3), Excision (0/2) | 6–12 months | IGM | 5 | [72] |
62 | Postolova A | 2020 | USA | 19 | Non-Randomized | 33.5 | Antibiotic (3/19) | 36 (12–84 months) | IGM | 5 | [73] |
63 | Sheybani F | 2015 | Iran | 22 | Non-Randomized | 32.82 ± 6.26 (23–47) | Oral steroid (3/15), MTX (0/1), Oral steroid + MTX (0/6) | 11.91 ± 4.4 (6–22) | IGM | 5 | [7] |
64 | Avci M. E | 2015 | Turkey | 9 | Non-Randomized | 21–39 | Oral steroid (8/9) | – | IGM | 8 | [74] |
65 | Seo H. R. N | 2012 | Korea | IGM:58 TM:10 | Non-Randomized | IGM:33.5 TM:40 | Antibiotic + steroid (5/21), Antituberculosis (1/10), Excision (0/48) | IGM:11.71 TM:21 | IGM & TM | 7 | [75] |